Guideline for Diagnosis and Treatment of Infected Renal Cysts

Diagnostic Criteria

• A fever ≥ 38 °C together with acute flank or abdominal pain and localized tenderness should raise suspicion for renal cyst infection. 1
• Inflammatory markers ≥ CRP 50 mg/L or white‑blood‑cell count > 11 × 10⁹/L are highly suggestive of infection and help trigger further work‑up. 1

Imaging Strategy

• Initial imaging with renal ultrasound, computed tomography, or magnetic resonance imaging is recommended to exclude cyst hemorrhage or nephrolithiasis that can mimic infection. 2
• When the above laboratory thresholds are met in the setting of fever and focal pain, ¹⁸F‑FDG PET‑CT should be performed for definitive localization of the infected cyst, as it is more sensitive than contrast‑enhanced CT or MRI (recognizing occasional false‑negatives). 2

Empiric Antibiotic Therapy

• Begin a third‑generation intravenous cephalosporin (e.g., cefotaxime) with or without a fluoroquinolone (e.g., ciprofloxacin) to cover gram‑negative Enterobacteriaceae, the predominant pathogens in renal cyst infection. 1
• After clinical stabilization, transition to an oral fluoroquinolone, tailoring the regimen to culture results when available. [1][3]

Treatment Duration

• A minimum of 4–6 weeks of antimicrobial therapy is required for adequate eradication of infection. 1
• Longer courses should be considered for large cysts (>5 cm) or in immunocompromised patients, based on clinical response. 3

Indications for Percutaneous Drainage

• Drainage is indicated within 48–72 hours of antibiotic initiation if any of the following occur:

Drainage Technique

• Maintain the percutaneous drain until output ceases, indicating successful source control. 1
• For deep‑located cysts where percutaneous access is not feasible, surgical drainage should be considered. 1

ADPKD‑Specific Management Algorithm

Safety Considerations

• Fluoroquinolones carry increased risks of tendinopathy and aortic aneurysm/dissection; these risks must be discussed with patients, especially those with ADPKD who have underlying vascular abnormalities. 1
• Chronic NSAIDs should be avoided for pain control in ADPKD patients due to the potential for renal adverse effects. 2

Treatment of Renal Cyst Infection

Diagnostic Approach

• The Kidney International guideline recommends suspecting renal cyst infection in patients with fever, acute abdominal or flank pain, and increased white blood cell count and/or C-reactive protein level 4, 5, 6
• Diagnostic features indicating likely cyst infection include serum C-reactive protein ≥50 mg/l or white blood cell count >11 × 10^9/l 4, 5, 6
• Blood cultures should be obtained if a kidney cyst infection is suspected 4, 5, 6
• It is important to differentiate cyst infection from cyst hemorrhage or kidney stone 4, 5, 6

Antibiotic Treatment

• Lipid-soluble antibiotics are preferred due to better penetration into renal cysts 4, 5, 6
• The recommended duration of antibiotic therapy is 4-6 weeks 4, 5, 6
• Initial empiric therapy should target gram-negative Enterobacteriaceae bacteria 4, 5, 6

Interventional Management

• Percutaneous drainage should be considered in cases of isolation of pathogens unresponsive to antibiotic therapy, immunocompromised patients, or no response to 48-72 hours of antibiotic treatment 4, 5, 6, 7
• The percutaneous drain should be kept in place until drainage stops 7
• Surgical drainage may be necessary for deep cysts where percutaneous drainage is not feasible 7

Special Considerations

• Fluoroquinolones carry risks of tendinopathies and aortic aneurysms, especially in patients with kidney disease 4, 5, 6
• Inadequate duration of antibiotic therapy can lead to treatment failure 4, 5, 6
• Delayed source control in cases unresponsive to antibiotics can be a common pitfall 7

Management of Infected Renal and Hepatic Cysts

Empiric Antibiotic Therapy

• Initiate a third‑generation intravenous cephalosporin (e.g., ceftriaxone 1–2 g daily) with or without an intravenous fluoroquinolone (e.g., ciprofloxacin 400 mg q12 h) to cover gram‑negative Enterobacteriaceae, the predominant pathogens in cyst infections. 8
• Reserve combination therapy (cephalosporin + fluoroquinolone) for patients with severe disease manifestations such as sepsis, hemodynamic instability, or immunocompromised status. 8
• Avoid carbapenems and cefazolin as first‑line agents because of poor cyst‑fluid penetration; use them only when cultures confirm multidrug‑resistant organisms. 9

Treatment Duration and Transition

• Administer antimicrobial therapy for a minimum of 4–6 weeks for both renal and hepatic cyst infections, regardless of early clinical improvement. 8
• After 48–72 hours of clinical stabilization, switch from intravenous to oral fluoroquinolone therapy to complete the course. 8
• Extend the total treatment period for large cysts (>5–8 cm), immunocompromised patients, or when the clinical response is suboptimal. 8

Diagnostic Thresholds for Initiating Therapy

• Suspect cyst infection when fever ≥ 38 °C is accompanied by either C‑reactive protein ≥ 50 mg/L or white‑blood‑cell count > 11 × 10⁹/L. 8

Indications for Percutaneous Drainage (within 48–72 h)

• Perform percutaneous drainage if any of the following are present:

Drainage Technique and Outcomes

• Keep the percutaneous drain in situ until drainage ceases completely. 8
• When percutaneous access is not feasible for deep‑located cysts, surgical drainage should be considered. 8
• A meta‑analysis reported that approximately 64 % of infected cysts ultimately require drainage, and the combination of drainage plus antibiotics is more effective than antibiotics alone. 9

Special Considerations for Polycystic Liver Disease

• Although identifying the exact infected cyst can be challenging, drainage is still indicated when the above criteria are met. [8 & 9]

Safety Note on Fluoroquinolones (contextual)

• Fluoroquinolones remain the standard of care for cyst infections because of superior cyst penetration, despite known risks of tendinopathy and aortic complications. [8 & 9]